FY2025 EPS Estimates for Arvinas Raised by Leerink Partnrs

Arvinas, Inc. (NASDAQ:ARVN) – Equities research analysts at Leerink Partnrs boosted their FY2025 EPS estimates for Arvinas in a research report issued to clients and investors on Wednesday, November 5th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of ($0.16) per share for the year, up from their prior estimate of ($0.72). The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Leerink Partnrs also issued estimates for Arvinas’ Q4 2025 earnings at $0.02 EPS, FY2026 earnings at ($1.51) EPS and FY2027 earnings at ($1.59) EPS.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.27. Arvinas had a negative net margin of 18.73% and a negative return on equity of 9.77%. The business had revenue of $41.90 million for the quarter, compared to analyst estimates of $29.36 million. During the same period last year, the firm earned ($0.68) earnings per share. Arvinas’s revenue for the quarter was down 59.1% compared to the same quarter last year.

ARVN has been the subject of a number of other reports. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price target on shares of Arvinas in a research report on Tuesday, October 7th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $6.00 price objective (down from $8.00) on shares of Arvinas in a report on Wednesday, October 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Arvinas in a research report on Wednesday, October 8th. BTIG Research raised their price target on Arvinas from $10.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Finally, HC Wainwright cut their price objective on shares of Arvinas from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Eleven analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $16.34.

Arvinas Stock Up 6.3%

NASDAQ ARVN opened at $10.63 on Monday. The firm has a 50-day moving average price of $8.83 and a two-hundred day moving average price of $7.90. Arvinas has a 12-month low of $5.90 and a 12-month high of $28.70. The company has a market capitalization of $682.66 million, a P/E ratio of -13.12 and a beta of 2.38.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in shares of Arvinas by 475.5% in the third quarter. JPMorgan Chase & Co. now owns 214,779 shares of the company’s stock worth $1,830,000 after acquiring an additional 177,460 shares during the last quarter. Profund Advisors LLC increased its position in Arvinas by 29.6% during the 3rd quarter. Profund Advisors LLC now owns 19,602 shares of the company’s stock worth $167,000 after purchasing an additional 4,480 shares in the last quarter. State of Wyoming acquired a new position in Arvinas during the 3rd quarter worth approximately $68,000. AlphaQuest LLC lifted its stake in Arvinas by 35.1% in the 3rd quarter. AlphaQuest LLC now owns 26,450 shares of the company’s stock valued at $225,000 after purchasing an additional 6,877 shares during the last quarter. Finally, Arizona State Retirement System boosted its position in Arvinas by 23.0% in the third quarter. Arizona State Retirement System now owns 17,256 shares of the company’s stock valued at $147,000 after buying an additional 3,225 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Insider Buying and Selling at Arvinas

In other Arvinas news, Director Briggs Morrison acquired 30,000 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The stock was acquired at an average cost of $7.57 per share, for a total transaction of $227,100.00. Following the transaction, the director directly owned 76,021 shares in the company, valued at $575,478.97. This represents a 65.19% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 4.73% of the stock is currently owned by corporate insiders.

Arvinas announced that its board has authorized a share repurchase program on Wednesday, September 17th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 17.9% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.